Moderna (MRNA.US) — stock surged over 17% in response to the news that AstraZeneca’s (AZN.US) CEO said the company would run another trial on its coronavirus vaccine candidate amid questions over the drug’s effectiveness. Meanwhile Moderna's vaccine has already posted outstanding results in its late-stage trial. The company, in turn, is expected to seek an Emergency Use Authorization from the Food and Drug Administration within the next few days. Other drugmaker’s Pizer (PFE.US) and BioNTech (BNTX.US), which are also working on their own vaccine, gained 1.7% and 4.4%, respectively.
Moderna (MRNA.US) stock launched today’ s session with a bullish price gap and painted fresh all-time high at $130.00. However bulls failed to uphold momentum and price pulled back to the $119.27 level. Source: xStation5
US Open: U.S. stock indices slip slightly on the last trading day of 2025
US OPEN: Wall Street awaits FOMC minutes
DE40: DAX hits a 2.5-month high 📈 Rheinmetall jumps on renewed Russia–Ukraine tensions
US OPEN: Start of the week with mild discounts, amid geopolitical tensions
